|
|
Previous Article | Table of Contents | Next Article 
Interleukin-4 stimulates expression of urokinase-type-plasminogen activator
in cultured human foreskin microvascular endothelial cells
J Wojta, M Gallicchio, H Zoellner, EL Filonzi, JA Hamilton and K McGrath
Department of Diagnostic Haematology, Royal Melbourne Hospital, Parkville,
Victoria, Australia.
The effect of interleukin-4 (IL-4) on the fibrinolytic system of human
microvascular and macrovascular endothelial cells in culture was studied.
Only foreskin microvascular endothelial cells (EC) responded to IL-4
treatment with a dose- and time-dependent increase in urokinase- type
plasminogen activator (u-PA) (control: 3.0 +/- 0.8 ng/10(5) cells/24 h; 200
U/mL IL-4: 6.7 +/- 0.8 ng/10(5) cells/24 h), whereas human macrovascular EC
remained unaffected. A maximum effect was achieved with 200 U/mL IL-4.
Little u-PA activity was detected in the conditioned media of human
foreskin microvascular EC (HFMEC) treated without and with IL-4 before
plasmin treatment (control: 0.03 +/- 0.003 IU/10(5) cells/20 h; 200 U/mL
IL-4: 0.09 +/- 0.007 IU/10(5) cells/20 h). These values increased to 0.18
+/- 0.02 IU/10(5) cells/20 h and 0.53 +/- 0.04 IU/10(5) cells/20 h,
respectively, after plasmin treatment, indicating that u-PA is released by
HFMEC predominantly in its inactive precursor form single-chain u-PA
(scu-PA). u-PA activity increased also in the cell lysates of HFMEC up to
2.5-fold after IL-4 treatment. Plasminogen activator inhibitor type-1
(PAI-1) levels produced by HFMEC remained unaffected by IL-4, whereas
tissue-type plasminogen activator (t-PA) levels were slightly decreased
when HFMEC were treated with IL-4. These findings were also reflected in
the specific mRNA levels as determined by Northern blotting. u-PA-specific
mRNA increased significantly in HFMEC in the presence of IL-4, whereas t-PA
mRNA and PAI-1-specific mRNA in HFMEC and u-PA specific mRNA in human
saphenous vein EC (HSVEC) remained unaffected by IL-4 treatment. Our
findings suggest a role for IL-4 in the process of angiogenesis, in
addition to its known proliferative effect on human microvascular EC, by
increasing the fibrinolytic potential of such EC, thereby facilitating
extracellular proteolysis and cell migration.
Volume 81,
Issue 12,
pp. 3285-3292,
06/15/1993
Copyright © 1993 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Shimizu, R. N. Mitchell, and P. Libby
Inflammation and Cellular Immune Responses in Abdominal Aortic Aneurysms
Arterioscler Thromb Vasc Biol,
May 1, 2006;
26(5):
987 - 994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Netherton and D. H. Maurice
Vascular Endothelial Cell Cyclic Nucleotide Phosphodiesterases and Regulated Cell Migration: Implications in Angiogenesis
Mol. Pharmacol.,
January 1, 2005;
67(1):
263 - 272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Verbsky, D. A. Randolph, L. P. Shornick, and D. D. Chaplin
Nonhematopoietic Expression of Janus Kinase 3 Is Required for Efficient Recruitment of Th2 Lymphocytes and Eosinophils in OVA-Induced Airway Inflammation
J. Immunol.,
March 1, 2002;
168(5):
2475 - 2482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-i. Fukushi, M. Ono, W. Morikawa, Y. Iwamoto, and M. Kuwano
The Activity of Soluble VCAM-1 in Angiogenesis Stimulated by IL-4 and IL-13
J. Immunol.,
September 1, 2000;
165(5):
2818 - 2823.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Ribatti, M. Presta, A. Vacca, R. Ria, R. Giuliani, P. Dell'Era, B. Nico, L. Roncali, and F. Dammacco
Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo
Blood,
April 15, 1999;
93(8):
2627 - 2636.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Wang, H. J. Chen, K. N. Giedd, A. Schwartz, P. J. Cannon, and L. E. Rabbani
T-Cell Lymphokines, Interleukin-4 and Gamma Interferon, Modulate the Induction of Vascular Smooth Muscle Cell Tissue Plasminogen Activator and Migration by Serum and Platelet-Derived Growth Factor
Circ. Res.,
December 1, 1995;
77(6):
1095 - 1106.
[Abstract]
[Full Text]
|
 |
|
|
|